Skip to main content

A case report of rhino-facial mucormycosis in a non-diabetic patient with COVID-19: a systematic review of literature and current update



COVID-19 disease may be associated with a wide range of bacterial and fungal infections. We report a patient with COVID-19 infection who developed rhino-facial mucormycosis during treatment with corticosteroids.

Case presentation

A 59-year-old non-diabetic male patient was admitted with a diagnosis of COVID-19 based on positive RT-PCR and CT of the lungs. Due to sever lung involvement, he was treated with methylprednisolone. The patient was re-admitted to hospital, due to nasal obstruction and left side facial and orbital swelling, several days after discharge. In sinus endoscopic surgery, debridement was performed and the specimens were sent to pathology and mycology laboratories. A nasal biopsy showed wide hyphae without septa. The sequenced PCR product revealed Rhizopus oryzae. Despite all medical and surgical treatment, the patient died. In addition, the characteristics of patients with COVID-19-associated mucormycosis were reviewed in 44 available literatures. In most studies, diabetes mellitus was the most common predisposing factor for mucormycosis.


Our report highlights the need for assessing the presence of mucormycosis in patients with COVID-19 and also it shows that physicians should consider the potential for secondary invasive fungal infections in COVID-19 cases.

Peer Review reports


COVID-19 is a viral disease of the respiratory tract that continues to be a major health issue worldwide. The disease is associated with common symptoms such as fever, dry cough, fatigue, and shortness of breath and sometimes in severe cases, leads to acute respiratory distress syndrome (ARDS) [1]. On the other hand, the use of corticosteroids to modulating lung injury and reduce mortality in COVID-19 patients may be exposes the patient to opportunistic bacterial and fungal infections [2].

Invasive pulmonary aspergillosis is one of the fungal diseases that complicates COVID-19 manifestations [3]. Moreover, mucormycosis as an opportunistic fungal infection can progress rapidly in immunocompromised patients. The most common clinical form of this fungal infection is rhino-cerebral mucormycosis [4]. We reported a case of rhino facial mucormycosis in a 59-year-old non-diabetic male patient with COVID-19 following corticosteroid treatment, which eventually resulted in death.

Case presentation

A 59-year-old non-diabetic male patient without any underlying disease with clinical symptoms of cough, shortness of breath, and oxygen saturation of 76% was admitted to Razi Hospital, Qazvin, Iran. His vital signs included body temperature of 37.6 °C, blood pressure value of 140/85 (mm Hg) and oxygen saturation of 76%. Positive results of chest X-ray test (CXR), computed tomography (CT) scan of lungs and positive reverse transcriptase polymerase chain reaction (RT-PCR) showed a definite diagnosis of COVID-19 (Fig. 1).

Fig. 1
figure 1

Computed tomography (CT) scan of the chest of a patient with COVID-19 shows multiple patchy ground-glass opacities

He was treated with remdesivir injection at a dose of 250 mg stat and then 100 mg daily. The patient was under supportive care for six days, and thereafter methylprednisolone was administered at a dose of 250 mg stat and then 125 mg for 3 days. After 10 days, the patient was discharged while he was relatively in good general condition. Four days after his discharge, the patient was re-admitted to hospital because of nasal obstruction and left side facial and orbital swelling. Table 1 shows the laboratory findings of the patient during both COVID-19 and mucormycosis. Subsequently, the patient visited by an infectious disease specialist and due to the involvement of the left ethmoid, sphenoid, and maxillary sinuses, a CT scan was performed (Fig. 2). In sinus endoscopic surgery, by Rhinologist, severe involvement and necrosis of the left side lateral nasal wall, floor, and septum as well as left ethmoid and sphenoid sinuses were observed and also destruction of the left orbital floor and medial wall were observed. Since clinical results confirmed the possibility of mucormycosis in the patient, treatment with IV liposomal amphotericin B (3 mg/kg/day, according to local guidelines [5]) was started. In addition, the patient underwent daily paranasal sinuses debridement and irrigation with diluted amphotericin B. Biopsy of sinonasal area was made and the specimens were sent to both pathology and mycology laboratories. Examination of the results with haematoxylin and eosin (H&E) staining and direct experiment with 10% potassium hydroxide (KOH) showed irregular hyphae, wide and aseptate (Fig. 3).

Table 1 The measured hematological biomarkers in blood of the patient
Fig. 2
figure 2

CT scan shows involvement of the left ethmoid, sphenoid, maxillary and paranasal sinuses in a patient with mucormycosis

Fig. 3
figure 3

a Presence of irregular and non-septate hyphae in H&E staining of pathology. b Observation of broad aseptate hyphae in surgical debridement in direct examination (10% KOH). c and d Lactophenol cotton blue (LCB) mount showed nonseptate hyphae, rhizoids and spore-filled sporangiophores

In addition, the sample was inoculated on PDA (Sigma-Aldrich,UK) and was incubated for 4–5 days at 37 °C. After colony growth, non- septate hyphae, rhizoids and spore-filled sporangiophores were observed in slides prepared with LCB (Fig. 3). The antifungal susceptibility testing was performed in 96-well plates by following the M38-A2 guidelines of the CLSI for in vitro testing. MIC values against AMB, ITC and VRC were 0.5 mg/mL, 16 mg/mL and 32 mg/mL, respectively. In the next step, DNA extraction was carried out using the glass beads and phenol:chloroform:isoamyl alcohol (25:24:1) method, previously described [6]. The fungal isolate was identified by molecular analysis of ITS1-5.8S-ITS2 region using the primers for ITS1 (5′-TCCGTAGGTGAACCTGCGG-3′) and ITS4 (5′-TCCTCCGCTTATTGATATGC-3′). The sequenced PCR product showed 100% sequence identity with R. oryzae and it was registered in the GenBank database under the assigned accession number MW317184. Sequence was aligned with using the ClustalW algorithm as implemented in Bioedit version 7 ( The molecular diversity of the sample was estimated by phylogenetic analysis via MEGA7 software. In order to compare the sequences with available DNA sequences in GenBank, the nucleotide BLAST with the BLASTn algorithm was applied through CLUSTAL omega ( The protocols were conducted based on the ML method using the Tamura-Nei model. The number of bootstrap replications was considered to be 1000 (Fig. 4). Because of the progression of the disease and the involvement of the cheeks and orbit, necrotic tissues were removed. Despite all measures, the patient unfortunately expired on the seventh day of his admission due to loss of consciousness and involvement of central nervous system.

Fig. 4
figure 4

The phylogenetic tree of isolates of Rhizopus oryzae. Based on ITS sequence from a patient with mucormycosis and GenBank sequences of some related species were estimated in MEGA7 using the ML analyses based on 1,000 bootstrap replications

Discussion and conclusions

COVID-19 disease has a rapid and widespread distribution with mild to severe symptoms. Supportive care, corticosteroids and remedial drugs are good treatment options in COVID-19. On the other hand, due to the use of steroids, these patients may be susceptible to invasive mould infections. Furthermore, diabetes mellitus complicates the management of Covid-19 infection.

Mucormycosis is an acute fungal infection caused by the members of mucoraceae family. Mucormycosis in uncontrolled diabetic patients and immunocompromised is an opportunistic and fatal fungal disease [7]. The most common clinical manifestation of mucormycosis in immunocompromised patients is the rhino-orbito-cerebral form [8]. Infection begins in the nasal cavities and paranasal sinuses. The symptoms of mucormycosis include one-sided facial swelling, headache, fever, inflammation, eyelid drooping and black lesions on nasal that the disease spreads rapidly [9]. Infarction and necrosis of host tissues occur due to invasion of non-septate hyphae [10]. Methods for diagnosing mycromycosis include histopathology, direct testing, and culture of clinical specimens [11]. The first line of management of mucormycosis is recommended injection of liposomal amphotericin B. In case of intolerance of the treatment regimen or general weakness of the patient, azole compounds such as Posaconazole and Isavuconazole can be used [5].

The database search using the terms ‘‘COVID’’ OR ‘‘SARS-CoV2’’ OR ‘‘Coronavirus’’ AND "Mucor" OR ‘‘Zygomycosis’’ revealed a total of 44 articles. The characteristics of patients with COVID-19-associated mucormycosis were shown in Table 2.

Table 2 Characteristics of patients with mucormycosis and COVID-19 reported in the literature

Review of literature published till June 2021 shows that the most cases are related to mucormycosis in COVID-19 patients was in India with 110 cases [12,13,14,15,16,17,18,19,20,21,22,23,24,25], followed by Iran (20 cases) [26,27,28,29,30], Turkey (12 cases) [31, 32], Egypt (11 cases) [33, 34], the United States and (10 cases) [35,36,37,38,39,40,41,42,43], the Netherlands (4 cases) [44], UK and Spain (2 cases) [45,46,47]. Furthermore, a case of mucormycosis in COVID-19 patients has been published from Brazil [48], Australia [49], France [50], Mexico [51], Italy [52] and Iraq [53]. Studies show that the median age of the patients was 53.4 years (range 22–86) with a higher prevalence of mucormycosis in men (75.7%). The association of mucormycosis with uncontrollable diabetes has been proven [54]. Diabetes mellitus was the most common predisposing factor (73.4%) for mucormycosis in COVID-19 patients [14, 15, 27, 32, 35, 44]. In 5 cases (2.8%), no risk factors for mucormycosis were reported [14, 21, 29, 37]. In our reported case, corticosteroid-related hyperglycemia was observed in a patient with no history of diabetes. Predisposing factors for mucormycosis include diabetes mellitus, neutropenia, corticosteroid use, and immunodeficiency, among which diabetes is the most common risk factor linked with mucormycosis [55]. The severity of COVID-19 infection and its dangerous consequences are higher in individuals with diabetes. Glucocorticoids reduce mortality in patients with COVID-19 by reducing cytokine storm. Nevertheless, corticosteroids can increase the risk of fungal and bacterial secondary infections [56]. Therefore, use of steroids should be avoided in mild to moderate COVID-19 cases as they lead to dangerous results. Reports indicate that 82% of patients received corticosteroids.

The mean duration from between diagnosis of COVID-19 and the onset of symptoms of mucormycosis was 15 days [15, 18]. Studies show that the most common clinical manifestation of mucormycosis is rhino-facial, followed by pulmonary and disseminated form. Herein, we report a case of mucormycosis in a 59-year-old male non-diabetic with COVID-19. The patient developed rhino-facial mucormycosis after the initiation of corticosteroid. The mean duration between diagnosis of COVID-19 infection and the onset of symptoms of mucormycosis was 15 days [13, 15, 57]. The present case indicates that in the presence of COVID-19, even short-term treatment with corticosteroids may be a predisposing factor in leading the patient to rhino-orbital mucormycosis. Studies show that glucose control, timely treatment with liposomal amphotericin B, and surgical debridement are effective in the management of mucormycosis. The prognosis of the disease depends on factors such as early diagnosis and management to limit the spread of infection into the intracranial space [5, 58]. This study, in line with the results of other studies, reveals that the possible occurrence of secondary invasive fungal infections in patients with COVID-19 infection should not be neglected. Effort to maintain blood sugar and the rational use of corticosteroids in COVID-19 patients is recommended to reduce the risk of mucormycosis.

Availability of data and materials

All data analyzed during this study are included in this published article.



Coronavirus disease 2019


Acute respiratory distress syndrome


Hematoxylin and eosin


Potato dextrose agar


Clinical and Laboratory Standards Institute


Minimum inhibitory concentration

R. oryzae :

Rhizopus oryzae




  1. Gibson PG, Qin L, Puah S. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med J Aust. 2020;213(2):54–6.

    Article  PubMed  Google Scholar 

  2. Szarpak L, Wisco J, Boyer R. How healthcare must respond to ventilator-associated pneumonia (VAP) in invasively mechanically ventilated COVID-19 patients. Am J Emerg Med. 2021.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Helleberg M, Steensen M, Arendrup MC. Invasive aspergillosis in patients with severe COVID-19 pneumonia. Clin Microbiol Infect. 2021;27(1):147–8.

    Article  CAS  PubMed  Google Scholar 

  4. Gamaletsou MN, Sipsas NV, Roilides E, Walsh TJ. Rhino-orbital-cerebral mucormycosis. Curr Infect Dis Rep. 2012;14(4):423–34.

    Article  PubMed  Google Scholar 

  5. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SC, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mohammadi F, Hashemi SJ, Seyedmousavi SM, Akbarzade D. Isolation and characterization of clinical triazole resistance Aspergillus fumigatus in Iran. Iran J Public Health. 2018;47(7):994.

    PubMed  PubMed Central  Google Scholar 

  7. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54:S23–34.

    Article  PubMed  Google Scholar 

  8. Talmi YP, Goldschmied-Reouven A, Bakon M, Barshack I, Wolf M, Horowitz Z, Berkowicz M, Keller N, Kronenberg J. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol Head Neck Surg. 2002;127(1):22–31.

    Article  PubMed  Google Scholar 

  9. Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin N Am. 2000;33(2):349–65.

    Article  CAS  Google Scholar 

  10. Challa S. Mucormycosis: Pathogenesis and pathology. Current Fungal Infection Reports. 2019;13(1):11–20.

    Article  Google Scholar 

  11. Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. J Fungi. 2020;6(4):265.

    Article  CAS  Google Scholar 

  12. Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12(9):1.

    Google Scholar 

  13. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, Puri GD, Chakrabarti A, Agarwal R. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021;19:1–10.

    Google Scholar 

  14. Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi K, Kale PG, Rao PS, Haldipur D, Bonanthaya K. SARS-CoV-2, uncontrolled diabetes and corticosteroids—an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021;73:1–8.

    Google Scholar 

  15. Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021;69(2):244.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol. 2021;69(4):1002.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021;135(5):442–7.

    Article  CAS  PubMed  Google Scholar 

  18. Revannavar SM, Supriya P, Samaga L, Vineeth V. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep. 2021;14(4):e241663.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Mishra N, Mutya V, Thomas A. A case series of invasive mucormycosis in patients with COVID-19 infection. Int J Otorhinolaryngol Head Neck Surg. 2021;7(5):867–70.

    Article  Google Scholar 

  20. Saldanha M, Reddy R, Vincent MJ: of the article: paranasal mucormycosis in COVID-19 patient. Indian Journal of Otolaryngology and Head & Neck Surgery 2021:1–4.

  21. Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: a case report. Int J Surg Case Rep. 2021;82:105957.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Nehara HR, Puri I, Singhal V, Sunil I, Bishnoi BR, Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: case series from the north-western part of India. Indian J Med Microbiol. 2021;39(3):380–3.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Rao R, Shetty AP, Nagesh CP. Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: clinico-radiological features. Indian J Ophthalmol. 2021;69(6):1627–30.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Meshram HS, Kute VB, Chauhan S, Desai S. Mucormycosis in post-COVID-19 renal transplant patients: a lethal complication in follow-up. Transpl Infect Dis. 2021;2021:e13663.

    Google Scholar 

  25. Shah D, Talwar D, Kumar S, Acharya S, Dubey A: Mucormycosis as a complication of LONG COVID: A case series. 2021.

  26. Karimi-Galougahi M, Arastou S, Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol. 2021;1:1029–30.

    Article  Google Scholar 

  27. Ahmadikia K, Hashemi SJ, Khodavaisy S, Getso MI, Alijani N, Badali H, Mirhendi H, Salehi M, Tabari A, Mohammadi Ardehali M: The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis. Mycoses 2021.

  28. Tabarsi P, Khalili N, Pourabdollah M, Sharifynia S, Naeini A, Ghorbani J, Mohamadnia A, Abtahian Z, Askari E: COVID-19 associated rhinosinusitis mucormycosis due to Rhizopus arrhizus: A rare but potentially fatal infection occurring after treatment with corticosteroids. 2021.

  29. Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R: Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report. Eur J Ophthalmol 2021

  30. Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, Rezaie Y, Rajaeih S, Alijani N, Barac A: Mucormycosis in patients with COVID‐19: a cross‐sectional descriptive multicenter study from Iran. Mycoses 2021.

  31. Sargin FAM, Karaduman S, Sungurtekin H. Severe rhinocerebral mucormycosis case developed after COVID 19. J Bacteriol Parasitol. 2021;12:386.

    Google Scholar 

  32. Bayram N, Ozsaygılı C, Sav H, Tekin Y, Gundogan M, Pangal E, Cicek A, Özcan İ. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. Jpn J Ophthalmol. 2021;1:1–11.

    Google Scholar 

  33. Ashour MM, Abdelaziz TT, Ashour DM, Askoura A, Saleh MI, Mahmoud MS. Imaging spectrum of acute invasive fungal rhino-orbital-cerebral sinusitis in COVID-19 patients: a case series and a review of literature. J Neuroradiol. 2021.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Fouad YA, Abdelaziz TT, Askoura A, Saleh MI, Mahmoud MS, Ashour DM, Ashour MM. Spike in rhino-orbital-cerebral mucormycosis cases presenting to a tertiary care center during the COVID-19 pandemic. Front Medicine. 2021;8:1.

    Article  Google Scholar 

  35. Dallalzadeh LO, Ozzello DJ, Liu CY, Kikkawa DO, Korn BS. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. Orbit. 2021;1:1–4.

    Google Scholar 

  36. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42(264):e265–e264.

    Google Scholar 

  37. Placik DA, Taylor WL, Wnuk NM. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. Radiol Case Rep. 2020;15(11):2378–81.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Mekonnen ZK, Ashraf DC, Jankowski T, Grob SR, Vagefi MR, Kersten RC, Simko JP, Winn BJ. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthal Plast Reconstr Surg. 2021;37(2):e40.

    Article  PubMed  Google Scholar 

  39. Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. J Med Cases. 2021;12(3):85.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Johnson AK, Ghazarian Z, Cendrowski KD, Persichino JG. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol. 2021;32:64–7.

    Google Scholar 

  41. Kanwar A, Jordan A, Olewiler S, Wehberg K, Cortes M, Jackson BR. A fatal case of Rhizopus azygosporus pneumonia following COVID-19. J Fungi. 2021;7(3):174.

    Article  Google Scholar 

  42. Khatri A, Chang K-M, Berlinrut I, Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient–case report and review of literature. J Med Mycol. 2021;187:101125.

    Article  Google Scholar 

  43. Khan N, Gutierrez CG, Martinez DV, Proud KC. A case report of COVID-19 associated pulmonary mucormycosis. Arch Clin Cases. 2020;7(3):2027.

    Article  Google Scholar 

  44. Buil JB, van Zanten AR, Bentvelsen RG, Rijpstra TA, Goorhuis B, van der Voort S, Wammes LJ, Janson JA, Melchers M, Heusinkveld M. Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. Eurosurveillance. 2021;26(23):2100510.

    Article  CAS  PubMed Central  Google Scholar 

  45. Krishna V, Morjaria J, Jalandari R, Omar F, Kaul S. Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection. IDCases. 2021;23:e01172.

    Article  Google Scholar 

  46. Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS, Thursz M, Manousou P, Corbett R, Goldin R. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020;1(6):e245–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Arana C, Cuevas Ramírez RE, Xipell M, Casals J, Moreno A, Herrera S, Bodro M, Cofan F, Diekmann F, Esforzado N. Mucormycosis associated with covid19 in two kidney transplant patients. Transpl Infect Dis. 2021;89:e13652.

    Google Scholar 

  48. do Monte Junior ES. Rare and fatal gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: a case report. Clin Endosc. 2020;53(6):746.

    Article  PubMed Central  Google Scholar 

  49. Zurl C, Hoenigl M, Schulz E, Hatzl S, Gorkiewicz G, Krause R, Eller P, Prattes J. Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi. 2021;7(2):88.

    Article  CAS  Google Scholar 

  50. Bellanger A-P, Navellou J-C, Lepiller Q, Brion A, Brunel A-S, Millon L, Berceanu A: Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. Infectious Diseases Now 2021.

  51. Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus. 2021;13(2):1.

    Google Scholar 

  52. Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, Simeo R, Buselli A, Rizzo D, Bussu F. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2020;16:1–6.

    Google Scholar 

  53. Farid HA, Hashim AR, Hasrat NH. Rhinocerebral mucormycosis as a COVID-19-related complication: a case report from Basra City, Southern Iraq. J Glob Sci Res. 2021;6(5):1369–74.

    Google Scholar 

  54. Rammaert B, Lanternier F, Poirée S, Kania R, Lortholary O. Diabetes and mucormycosis: a complex interplay. Diab Metab. 2012;38(3):193–204.

    Article  CAS  Google Scholar 

  55. Reid G, Lynch III JP, Fishbein MC, Clark NM: Mucormycosis. In: Seminars in respiratory and critical care medicine: 2020: Thieme Medical Publishers; 2020: 099114

  56. Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect. 2021;27(1):9.

    Article  CAS  PubMed  Google Scholar 

  57. Paul SS, Kumar R, Meena VP, Ramprasad A, Garg P, Keri VC, Singh K, Dhir A, Sakhtivel P, Vig S: Clinical characteristics and outcomes of 16 cases with COVID19 and mucormycosis: experience from a tertiary care center in India and review of literature. 2021.

  58. Patel A, Kaur H, Xess I, Michael J, Savio J, Rudramurthy S, Singh R, Shastri P, Umabala P, Sardana R. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26(7):944.

    Article  PubMed  CAS  Google Scholar 

Download references


The authors would like to thank the medical staff of the Razi Hospital in Qazvin, Iran.


This study was financially supported by the Research Deputy of Qazvin University of Medical Sciences and the ethics approval code of this research is IR.QUMS.REC.1399.357.

Author information

Authors and Affiliations



FM responsible for designing the manuscript and mycological analysis. MB and NH collaboration in mycological experiments. SS general ENT surgeon. All authors contributed to writing of the final version of the paper.

Corresponding author

Correspondence to Faezeh Mohammadi.

Ethics declarations

Ethics approval and consent to participate

The ethical approval was required and provided for this study, as stated by our institutional review board.

Consent for publication

The consent form has been signed by the family members of the patient.

Competing interests

The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohammadi, F., Badri, M., Safari, S. et al. A case report of rhino-facial mucormycosis in a non-diabetic patient with COVID-19: a systematic review of literature and current update. BMC Infect Dis 21, 906 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: